Ocular Therapeutix
Open
$9.08
Prev. Close
$9.09
High
$9.08
Low
$8.91
Market Snapshot
$1.95B
-6.7
-1.25
$63.72M
325
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 325 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 325 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Recently from Cashu
Ocular Therapeutix Advances AXPAXLI for Wet AMD with Positive Phase 3 Trial Results
Ocular Therapeutix is advancing decisively in its discussions with the FDA concerning AXPAXLI, a promising therapeutic candidate for wet age-related macular degeneration (AMD). This serious condition…
Analysts Split on Ocular Therapeutix Pipeline, Regulatory and Commercial Risks
Analysts Split on Ocular Therapeutix's Pipeline Prospects Five independent analyst reports published over the past three months portray a divided view of Ocular Therapeutix, the specialty ophthalmolog…
Divergent Analyst Views Highlight Ocular Therapeutix Clinical and Regulatory Uncertainty
Divergent analyst reports shine a light on clinical and regulatory uncertainty at Ocular Therapeutix Ocular Therapeutix faces a split narrative from sell-side analysts who, over the past three months,…
Analysts Diverge on Ocular Therapeutix Amid Clinical and Regulatory Ambiguity
Analyst divergence highlights clinical and regulatory ambiguity at Ocular Therapeutix Ocular Therapeutix faces a split of opinion among five analysts who publish divergent takes on the company’s near-…